Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cancer Genetics Inc (CGIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Cancer Genetics Appoints Glenn Miles as Chief Financial Officer

Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of Glenn Miles as Chief...

CGIX : 0.50 (-5.66%)
Will Cancer Genetics (CGIX) Report Negative Earnings Next Week? What You Should Know

Cancer Genetics (CGIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CGIX : 0.50 (-5.66%)
Cancer Genetics Enters Strategic Partnership with Genecast Biotechnology to Commercialize Tissue of Origin(R) Test in China

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced that it has signed an exclusive...

CGIX : 0.50 (-5.66%)
Cancer Genetics Issues Letter to Shareholders

Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the publication of a letter to shareholders...

CGIX : 0.50 (-5.66%)
Cancer Genetics and Cellaria Partner on Precision Medicine Tools

Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, and Cellaria, LLC, a scientific innovator that develops...

CGIX : 0.50 (-5.66%)
Robbins Arroyo LLP: Cancer Genetics, Inc. (CGIX) Sued by Shareholders in Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Cancer Genetics, Inc. (NASDAQ: CGIX) have filed a class action complaint against the company's officers...

CGIX : 0.50 (-5.66%)
Cancer Genetics Offers Oncomine Comprehensive Assay to Drive Clinical Trials

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the successful CLIA validation...

CGIX : 0.50 (-5.66%)
Chardan Advises NovellusDX in Cross-Border Biotech Merger

Chardan, a global investment bank, announced today that the firm acted as exclusive financial advisor to NovellusDX, Ltd., a leader in functional genomics, for the firm's agreement to merge with a newly...

CGIX : 0.50 (-5.66%)
Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, and NovellusDx, Ltd., a leader in functional...

CGIX : 0.50 (-5.66%)
Cancer Genetics Reports Second Quarter 2018 Financial Results and Provides Strategic Business Updates

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced financial and operating...

CGIX : 0.50 (-5.66%)
Cancer Genetics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Cancer Genetics, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time....

CGIX : 0.50 (-5.66%)
Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it will release its financial results for the...

CGIX : 0.50 (-5.66%)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cancer Genetics, Inc. (CGIX) and Lead Plaintiff Deadline - June 4, 2018

NEW YORK, NY / ACCESSWIRE / May 16, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Cancer Genetics, Inc.("Cancer Genetics" or the "Company") (NASDAQ:...

CGIX : 0.50 (-5.66%)
DEADLINE ALERT: Shareholder Class Action Filed Against Cancer Genetics, Inc. - CGIX

RADNOR, PA / ACCESSWIRE / May 15, 2018 / Kaskela Law LLC reminds Cancer Genetics, Inc. (NASDAQ: CGIX) ("Cancer Genetics" or the "Company") shareholders that a class action lawsuit has been filed on behalf...

CGIX : 0.50 (-5.66%)
Cancer Genetics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Cancer Genetics, Inc. (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:30 AM Eastern Time.

CGIX : 0.50 (-5.66%)
Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates

Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced financial and operating results for the first quarter...

CGIX : 0.50 (-5.66%)
Cancer Genetics to Report First Quarter 2018 Financial Results on May 15, 2018

Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it will release its financial results for the first...

CGIX : 0.50 (-5.66%)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Cancer Genetics, Inc. (CGIX) & Lead Plaintiff Deadline - June 4, 2018

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Cancer Genetics, Inc. ("Cancer Genetics" or the "Company") (NASDAQ:CGIX) and certain...

CGIX : 0.50 (-5.66%)
Important Deadline Notice for Cancer Genetics, Inc. Shareholders - CGIX

RADNOR, PA / ACCESSWIRE / May 10, 2018 / Kaskela Law LLC reminds Cancer Genetics, Inc. (NASDAQ: CGIX) ("Cancer Genetics" or the "Company") shareholders that a class action lawsuit has been filed on behalf...

CGIX : 0.50 (-5.66%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cancer Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline - CGIX

NEW YORK, NY / ACCESSWIRE / May 9, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Cancer Genetics, Inc. ("Cancer Genetics" or the "Company") (NASDAQ: CGIX) and certain...

CGIX : 0.50 (-5.66%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA +5.08
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures are mostly 1 to 2 cents in the red at midday, despite a decent round of export sales data. Ethanol is also lower at the moment. This morning’s Export Sales report showed net 18/19 sales on the high side of trade expectations at 892...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar